Previous Article | Next Article 
Journal of Virology, December 1999, p. 10245-10253, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Adenoviruses Activate Human Dendritic Cells without Polarization
toward a T-Helper Type 1-Inducing Subset
Delphine
Rea,1,*
Frederik H. E.
Schagen,2
Rob C.
Hoeben,2
Majid
Mehtali,3
Menzo J. E.
Havenga,4
Rene E. M.
Toes,1
Cornelis J. M.
Melief,1 and
Rienk
Offringa1
Department of Immunohematology and Blood
Bank1 and Laboratory of Molecular
Carcinogenesis, Department of Molecular Cell
Biology,2 Leiden University Medical Center, 2300 RC Leiden, and IntroGene B.V., 2301 CA
Leiden,4 The Netherlands, and Transgene
S.A., 67000 Strasbourg, France3
Received 1 June 1999/Accepted 3 September 1999
 |
ABSTRACT |
Human monocyte-derived dendritic cells (DC) infected with
recombinant adenoviruses (rAd) are promising candidate vaccines for
inducing protective immunity against pathogens and tumors. However,
since some viruses are known to negatively affect DC function, it is
important to investigate the interactions between rAd and DC. We now
show that infection by rAd enhances the immunostimulatory capacity of
immature human monocyte-derived DC through the upregulation of the
costimulatory molecules CD80, CD86, and CD40 and the major histocompatibility complex class I and II molecules. Although rAd
infection fails to induce the secretion of interleukin-12 (IL-12) and
only marginally induces the expression of the DC maturation marker
CD83, it acts in synergy with CD40 triggering in rendering DC fully
mature. rAd-infected DC triggered through CD40 produce more IL-12 and
are more efficient in eliciting T-helper type 1 responses than DC
activated by CD40 triggering only. rAd lacking one or more of the early
regions, E1, E2A, E3, and E4, which play an important role in
virus-host cell interactions are equally capable of DC activation.
Efficient DC infection requires a high multiplicity of infection
(>1,000), a fact which can be attributed to the absence of the
coxsackievirus and adenovirus receptor on this cell type. Despite the
poor ability of DC to be infected by rAd, which may be improved by
targeting rAd to alternative DC surface molecules, DC infected with all
currently tested rAd constitute potent immunostimulators. Our study
provides new insights into the interactions between two highly
promising vaccine components, rAd and DC, and indicates that their
combination into one vaccine may be very advantageous for the
stimulation of T-cell immunity.
 |
INTRODUCTION |
Dendritic cells (DC), the most
potent antigen-presenting cells (APC) of the immune system, are crucial
initiators of T-lymphocyte responses against pathogens and tumors.
However, immature DC, which are specialized in antigen capture in
peripheral tissues, are poor stimulators of T cells. The development of
DC into immunostimulatory APC depends on their activation into mature
cells, characterized by high costimulatory and antigen-presenting
functions, loss of endocytic activity, secretion of interleukin-12
(IL-12), and ability to migrate to T-cell areas in the lymph nodes
(2). Stimuli capable of triggering DC maturation include
inflammatory cytokines, such as tumor necrosis factor alpha (TNF-
)
and IL-1; bacterial products, such as lipopolysaccharide (LPS)
(40, 41); and ligation of CD40 at the DC surface with
soluble CD40 ligand (CD40L) or upon interaction with CD40L-expressing
CD4+ T-helper (Th) type 1 (Th1) cells (8, 9,
29).
Given their remarkable immunostimulatory properties, DC are highly
promising vaccines against infectious diseases and cancer. Strategies
aiming at modifying DC to express foreign antigens utilize the uptake
of RNA, proteins, or peptide epitopes or the introduction of specific
genes. A major advantage of gene transfer over loading of DC with
proteins or peptides resides in the sustained production of the antigen
of choice over time, allowing DC to acquire the capacity to trigger T
cells while continuously presenting specific peptide epitopes. Several
groups have used recombinant adenoviruses (rAd) as vehicles for foreign
gene transfer into murine DC and have shown the value of these infected
DC as a preventive and therapeutic vaccine against cancer (6, 35,
46, 50). Furthermore, human DC engineered with rAd producing
melanoma antigens were found to elicit melanoma-specific cytotoxic T
lymphocytes (CTLs) in vitro (7).
Viruses capable of infecting DC exert contrasting effects on APC
function, leading either to immunity or to immunosuppression. DC
infected with influenza virus are able to bypass the requirement for
CD40 signals provided by CD4+ Th cells for the generation
of CTL responses (36). Influenza virus can indeed mimic CD40
signals and promote DC maturation in a fashion comparable to that of
CD40 ligation (10). In contrast, measles virus and human
immunodeficiency virus negatively interfere with DC function (5,
17, 20, 43), and measles virus-infected DC undergo apoptosis upon
CD40 ligation (44).
Because rAd-modified DC have been proposed as candidate vaccines
against pathogens and cancer, it is of crucial importance to explore
the DC-modulating effects of rAd. Human monocyte-derived DC obtained by
culturing of peripheral blood monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 can be easily generated in
sufficient numbers for clinical use (3, 38, 39) and, upon
CD40 ligation, become one of the most immunostimulatory human DC types
(2, 9, 37). We explored the impact of rAd infection on human
monocyte-derived DC biology and examined whether rAd could interfere
with CD40-mediated DC maturation. Our results show that rAd enhance the
immunostimulatory functions of DC by increasing their costimulatory and
antigen-presenting functions but do not trigger the secretion of IL-12.
Moreover, we show that rAd act in synergy with CD40 signals to promote
the full maturation of rAd-infected DC.
 |
MATERIALS AND METHODS |
Generation of DC from peripheral blood monocytes.
Human
peripheral blood mononuclear cells (PBMC) obtained from healthy donors
and isolated through Ficoll-Hypaque density centrifugation were plated
at 1.5 × 107 per well in six-well plates (Costar
Corp., Cambridge, Mass.) containing RPMI 1640 medium (Life
Technologies, Paisley, Scotland) supplemented with 2 mM glutamine and
10% fetal calf serum. After 2 h of incubation at 37°C, the
nonadherent cells were removed. The adherent fraction was cultured in
the presence of 800 U of GM-CSF (kindly provided by S. Osanto, LUMC,
Leiden, The Netherlands) per ml and 500 U of IL-4 (Pepro Tech Inc.,
Rocky Hill, N.J.) per ml for a total of 7 days. After 7 days, the DC
obtained were 80 to 95% pure and expressed typical markers of immature
cells, being CD14
, CD1a+, CD80+,
CD86+, HLA-DR+, HLA class I+, and
CD83
. Maturation of DC was carried out by activation
through CD40 with a CD8-CD40L fusion protein made of the extracellular
domain of human CD40L and of the murine CD8
chain (kindly provided
by Pierre Garrone, Schering Plough, Dardilly, France) (18).
Immature DC were collected and incubated at 5 × 105
cells/ml in 24-well plates in the presence of CD8-CD40L for 48 h.
In some experiments, lipopolysaccharide (LPS) (100 ng/ml) or poly(I · C) (50 µg/ml) (both from Sigma), monocyte-conditioned medium (MCM; 30% final volume), or TNF-
(100 ng/ml) (Pepro Tech Inc.) was used as a DC maturation agent.
rAd vectors.
rAd with deletions of E1 and E3 (AdTG6401), E1,
E3, and E2A (AdTG9542), and E1, E3, and E4 (AdTG9546) have been
described previously (30). rAd5CMV
-gal (referred to here
as AdCMV
-gal), which carries the Escherichia coli-derived
lacZ gene as a reporter, was obtained from Joachim Herz
(21). Adenovirus vector stocks were generated and purified
by double CsCl density centrifugation essentially as described
previously (16). To remove the CsCl, the virus bands were
mixed with 1 ml of dialysis buffer (TD buffer [25 mM Tris-Cl, 137 mM
NaCl, 5 mM KCl, 0.73 mM Na2HPO4, 0.9 mM CaCl,
0.5 mM MgCl2] [pH 7.45]) and dialyzed against 2 liters
of TD buffer, which was refreshed four times, at 4°C. The final
dialysis was performed with TD buffer containing 10% sucrose. Virus
stocks were stored at
80°C until further use. Virus stocks were
routinely tested for the presence of replication-competent adenoviruses (RCA) by PCR. In the stocks used, no RCA could be detected. The sensitivity of the assay is approximately 1 RCA per 5 × 107 PFU. Wild-type adenovirus type 5 was propagated on
HEpG2 cells and purified as described above.
Infection of DC with rAd.
Immature DC or mature DC (5 × 105) were resuspended in 500 µl of medium and
incubated with AdCMV
-gal at various multiplicities of infection
(MOI). After 2 h at 37°C, 500 µl of medium containing GM-CSF
was added. Transduction efficiency was assessed 24 h later by
measuring the expression of intracellular
-galactosidase by use of a
Fluoreporter lacZ flow cytometry kit (Molecular Probes Inc.,
Eugene, Oreg.) according to the manufacturer's instructions and a
FACScan (Becton Dickinson, San Jose, Calif.).
Analysis of the DC surface phenotype by flow cytometry.
DC
were stained on ice with mouse monoclonal antibodies for 30 min in
phosphate-buffered saline-1% fetal calf serum, followed by 30 min of
staining with fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse Fab fragments (Immunotech, Marseille, France) when
necessary, and were analyzed by flow cytometry. The following antibodies were used: phycoerythrin (PE)-anti-CD1a (Caltag
Laboratories, Burlingame, Calif.); PE-anti-CD80 (BB1), PE-anti-CD86
(FUN-1), FITC-anti-CD40 (5C3), PE-anti-CD54 (HA58), and PE-anti-CD58
(1C3) (all from Pharmingen, San Diego, Calif.); PE-anti-CD14 (L243), PE-anti-HLA-DR (m
P9), and PE- and FITC-conjugated isotype controls (all from Becton Dickinson); PE-anti-CD83 (Immunotech); and
FITC-anti-HLA class I (Serotec Inc., Raleigh, N.C.). Anti-
V
3 and
-
V
5 integrin antibodies were obtained from Chemicon
International, Inc. (Temecula, Calif.). The hybridoma cell line
producing the OKM1 antibody, directed against
M
2 integrins, was
obtained from the American Type Culture Collection. The
anti-coxsackievirus and adenovirus receptor (CAR) antibody was a kind
gift from J. M. Bergelson (Dana-Farber Cancer Institute, Boston, Mass.)
and has been previously described (24).
Antigen uptake experiments.
DC were resuspended in medium
buffered with 25 mM HEPES; FITC-bovine serum albumin (BSA) and
FITC-mannosylated BSA (Sigma) were each added at 1 mg/ml (final
concentration). The cells were incubated at 37 or 0°C to determine
background uptake. After 1 h, the cells were washed extensively
with ice-cold phosphate-buffered saline and analyzed by flow cytometry
with propidium iodide to eliminate dead cells.
Cytokine detection by ELISA.
Culture supernatants were
analyzed in serial twofold dilutions in duplicate. For IL-12 p40 and
gamma interferon (IFN-
) detection (sensitivity, 10 pg/ml), capture
monoclonal antibodies and biotinylated polyclonal antibodies were
obtained from Peter van de Meijde (BPRC, Rijswijk, The Netherlands).
IL-12 p70 was detected with a solid-phase sandwich enzyme-linked
immunosorbent assay (ELISA) kit (Diaclone Research, Besancon, France)
(sensitivity, 3 pg/ml). IL-10 was detected with a Pelikine compact
ELISA kit (CLB, Amsterdam, The Netherlands) (sensitivity, 3 pg/ml).
Antigen presentation assays.
The Mycobacterium
tuberculosis and M. leprae hsp65-specific
HLA-DR3-restricted CD4+ Th1 clone Rp15 1-1 used in this
study has been previously described (19) and recognizes an
hsp65 epitope corresponding to peptide residues 3 to 13 (referred to
here as p3-13) in the context of HLA-DR3 molecules. HLA-DR-matched
immature DC were pulsed with 10 µg of p3-13 per ml for 2 h at
37°C, washed extensively, and then infected with AdCMV
-gal at
1,000 PFU/cell, incubated with CD8-CD40L, or left untreated as
described above. After 48 h, Rp15 1-1 T cells (104)
were cultured with different numbers of gamma-irradiated (3,000 rads)
DC in triplicate in 96-well flat-bottom plates (Costar) for 3 days. In
some experiments, IL-12 (Sigma) was added at 250 pg/ml (final
concentration). [3H]thymidine incorporation was measured
on day 3 after a 16-h pulse. Before the addition of
[3H]thymidine, 50 µl of supernatant was collected from
each well, and supernatants from triplicate wells were pooled to
measure IFN-
production. For the generation of p3-13-specific T
cells from HLA-DR3+ individuals, immature DC, rAd-infected
DC, CD40-triggered DC, and rAd-infected CD40-stimulated DC pulsed with
10 µg of hsp65 per ml were cocultured with autologous nonadherent
responders in 24-well plates (Costar) at a ratio of 1 to 10. Five days
later, cultures were supplemented with 10% TCGF (Biotest, Dreieich,
Germany), fed every other day, and tested for the presence of
p3-13-specific and adenovirus-specific T cells 8 days later. In brief,
104 responders were cocultured with 5 × 104 gamma-irradiated autologous PBMC in triplicate, either
in the absence of antigen or in the presence of 1 µg of p3-13 per ml, 1 µg of 70K peptide (a DR3-binding negative control peptide) per ml,
or AdCMV
-gal. [3H]thymidine incorporation and IFN-
production were measured as described above.
Statistical analysis.
Covariance analysis was used to
compare T-cell proliferation and IFN-
production as a function of DC
numbers in immature uninfected DC, rAd-infected DC, and CD40-triggered
DC in the presence or absence of exogenous IL-12 (see Fig. 5).
 |
RESULTS |
Poor permissiveness of immature and mature human monocyte-derived
DC for rAd.
The susceptibility of human monocyte-derived DC to rAd
was evaluated by incubating immature DC with AdCMV
-gal at MOI
ranging from 10 to 2,500 PFU/cell. As shown in Fig.
1A, the number of infected DC increased
with the amount of virus used for infection, with less than 60% of
cells infected at an MOI of <100 and more than 96% of cells infected
at an MOI of >1,000. Importantly, no cytopathic effect was observed.
Cell viability, as determined by trypan blue exclusion, and viable cell
recovery were similar in infected and noninfected cultures for up to 4 days after infection. To assess whether the activation of immature DC
into mature immunostimulatory cells could modify their sensitivity to
rAd infection, DC stimulated with TNF-
, MCM, CD8-CD40L, LPS, or
poly(I · C) were incubated with AdCMV
-gal at 1,000 PFU/cell.
About 80% of TNF-
-, MCM-, or CD8-CD40L-stimulated DC were infected,
whereas LPS- and poly(I · C)-stimulated DC were considerably
less susceptible to rAd infection, with only about 30% of cells
infected (Fig. 1B).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Expression of -galactosidase ( gal) by immature and
mature DC after infection with AdCMV -gal. (A) Immature DC were
incubated with AdCMV -gal at MOI ranging from 10 to 2,500 and tested
24 h later with uninfected controls for gal expression.
Intracellular gal was detected with a Fluoreporter lacZ
flow cytometry kit. Results are expressed as the percentage of
gal-expressing cells and are representative of three independent
experiments. (B) DC either were allowed to mature in the presence of
TNF- , MCM, CD8-CD40L, LPS, or poly(I · C) or were cultured in
control medium and then were further incubated with AdCMV -gal at
1,000 PFU/cell. After 24 h, DC were analyzed for gal expression
as described above. Uninfected mature DC failed to express gal (data
not shown). The data are representative of two independent
experiments.
|
|
In order to understand the mechanisms underlying the poor
permissiveness of DC for rAd, we analyzed the expression of molecules involved in the binding and entry of the virus into host cells. The
initial attachment of rAd to the majority of human cell types is
mediated by its fiber capsid protein, which binds to the high-affinity CAR (4, 22). Major histocompatibility complex (MHC) class I
molecules may also serve as receptors for the fiber protein (23). Alternatively, rAd attachment to cells of
hematopoietic origin may occur upon binding of the penton base capsid
protein to
M
2 integrins (25). Subsequent virus entry
occurs via internalization into clathrin-coated vesicles after
interaction of the penton base protein with cellular
V
3 or
V
5 integrins (51). Immature DC, rAd-infected DC, and
DC stimulated with TNF-
, MCM, CD40L, LPS, and poly(I · C) all
lacked CAR and
V
3 integrins (Fig.
2). The
V
5 and
M
2 integrins
were expressed at higher levels on the surface of immature DC than in
rAd-infected DC or mature DC (Fig. 2). MHC class I molecules were
present in large amounts on immature DC, and their levels were further
increased after rAd infection and DC maturation (Fig. 2). As a control,
911 cells (16), which are highly permissive for rAd,
exhibited high levels of CAR,
V
3 and
V
5 integrins, and MHC
class I molecules and lacked
M
2 integrins (Fig. 2).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Surface expression of CAR, of the V 3, V 5,
and M 2 integrins, and of MHC class I molecules on immature DC,
rAd-infected DC, and different types of mature DC. DC were cultured in
control medium, infected with AdCMV -gal at 1,000 PFU/cell, or
allowed to mature with different stimuli and were analyzed by flow
cytometry 48 h later. 911 cells are shown as a positive control.
White histograms show background staining with isotype control
antibodies, and black histograms show specific staining. Mean
fluorescence intensities are indicated. The mean fluorescence
intensities of the background controls were less than 5. Comparable
results were obtained in two independent experiments.
|
|
In conclusion, optimal infection of human monocyte-derived DC by rAd
relies on the use of immature cells and requires high MOI. Mature DC
are more resistant than immature DC to rAd infection, but the degree of
this resistance strongly depends on the stimulus used to induce
maturation. The absence of CAR and the maturation-induced downregulation of the
V
5 and
M
2 integrins are in accordance with the low susceptibility of DC to rAd infection but cannot account
for the disparity in the degree of infection among the different types
of mature DC.
rAd infection increases the expression of costimulatory and MHC
molecules but does not polarize DC toward a Th1-inducing
phenotype.
The use of rAd-infected DC as potential vaccines in
human cancers requires that the virus does not subvert DC
immunostimulatory properties. We thus compared immature DC infected
with AdCMV
-gal with their uninfected counterparts and with
CD8-CD40L-stimulated DC for their cell surface phenotype. rAd infection
induced a marked upregulation of the costimulatory molecules CD80,
CD86, and CD40 and a significant increase in the expression of surface
MHC class II molecules, but the levels of expression of these markers
were lower than those obtained by stimulation with CD8-CD40L (Fig. 3). The expression of the adhesion
markers CD54 and CD58 was also increased by rAd infection (data not
shown). rAd infection induced only low levels of the DC maturation
marker CD83 (Fig. 3). These rAd-mediated phenotypic changes were
already detectable 24 h postinfection, peaked after 48 h, and
remained stable for at least 4 days (data not shown).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
rAd-mediated phenotypic changes after infection of
immature DC. Immature DC were infected with AdCMV -gal at 1,000 PFU/cell and analyzed 48 h later by flow cytometry for surface
expression of costimulatory molecules, MHC class II molecules, and DC
maturation marker CD83. Uninfected immature DC (medium control) and DC
allowed to mature by incubation with CD8-CD40L were tested in parallel.
White histograms show background staining with isotype control
antibodies, and black histograms show specific staining. Mean
fluorescence intensities are indicated. The mean fluorescence
intensities of background controls were less than 5. Comparable results
were obtained with DC generated from five different individuals.
|
|
Immature DC efficiently capture antigens mainly through
macropinocytosis and mannose receptor-mediated endocytosis and lose this property upon maturation (15, 40, 41, 48). When
rAd-infected DC were analyzed with respect to antigen uptake capacity,
the internalization of FITC-BSA and FITC-mannosylated BSA was found to
be significantly decreased in comparison with that in immature noninfected cells, but this downregulation was less pronounced than
that observed in CD8-CD40L-stimulated DC (Fig.
4A).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
rAd decrease the capacity of DC to internalize antigens
but do not trigger the secretion of IL-12 and IL-10. (A) Immature DC
were infected with AdCMV -gal at 1,000 PFU/cell, incubated with
CD8-CD40L, or cultured in medium alone. DC were tested 48 h later
for their ability to internalize FITC-BSA and FITC-mannosylated BSA and
were analyzed by flow cytometry. White histograms show background
autofluorescence, grey histograms show background uptake at 0°C, and
black histograms show specific uptake at 37°C, for which mean
fluorescence intensities are indicated. The results are representative
of two independent experiments. (B) DC were prepared as described
above, and culture supernatants collected 48 h later were tested
for the presence of IL-12 p40 and IL-10 by an ELISA. The results are
representative of five independent experiments.
|
|
A key feature of mature DC resides in their ability to produce IL-12, a
crucial cytokine for the priming of CD4+ Th1 responses and
CD4-dependent CTL responses (33). However, in contrast to
CD40 stimulation, rAd infection did not trigger IL-12 production by DC
(Fig. 4B). The possibility that rAd infection could promote an
alternative cytokine profile was also explored. Like immature
noninfected DC, rAd-infected DC did not produce IL-10, whereas low
levels of IL-10 could be detected after CD40 triggering (Fig. 4B), as
reported earlier (13).
The early regions of the adenovirus genome play an important role in
host immunosurveillance and virus-cell interactions (11, 26, 45,
52). Since in many of the recently developed rAd vectors, one or
more of these early regions have been deleted (30), we
analyzed the contributions of the different early genes to
adenovirus-mediated phenotypic changes in DC. The triple-deletion mutants (deletions of E1, E2A, and E3 and of E1, E3, and E4) and the
wild-type virus induced phenotypic changes similar to those observed
with the double-deletion mutant (deletion of E1 and E3) (AdCMV
-gal
virus) (Table 1). Of note, phenotypic
changes were not observed when DC were infected with rAd inactivated by
visible light in the presence of methylene blue. Such virus is still
capable of infecting DC but is incapable of expressing genes due to
multiple double-stranded DNA breaks (42) (data not shown).
This latter observation suggests that the expression of one or more
viral gene products is required for DC activation.
In conclusion, all currently tested rAd activate DC by upregulating
their surface expression of costimulatory and MHC molecules and by
downregulating their antigen uptake machinery. However, the lack of a
high level of CD83 expression and of IL-12 production indicates that
the activation of DC by rAd does not lead to their full maturation and
to their polarization toward a Th1-inducing phenotype.
rAd infection increases T-cell stimulatory functions of DC.
We
next studied the consequences of rAd-induced phenotypic changes for DC
immunostimulatory properties. Uninfected immature DC, rAd-infected DC,
and DC allowed to mature in the presence of CD8-CD40L were pulsed with
the p3-13-specific peptide epitope and tested for their ability to
stimulate the hsp65-specific CD4+ Th1 clone RP15 1-1. Consistent with the phenotypic analysis, rAd infection of DC
significantly (P, <0.001) enhanced the levels of T-cell
proliferation in an antigen-specific manner. However, CD40 ligation on
DC was a more potent stimulus than rAd infection (P,
<0.001) (Fig. 5A). In contrast to
CD40 ligation, rAd infection only weakly increased the T-cell-dependent
production of IFN-
(Fig. 5B). We analyzed whether the addition of
exogenous IL-12 would further increase rAd-infected DC stimulatory
potential. Figure 5A shows that exogenous IL-12 did not have any impact
on DC-induced T-cell proliferation. However, in combination with rAd-infected DC, IL-12 significantly enhanced the secretion of T-cell-derived IFN-
(P, <0.001) (Fig. 5B). Exogenous
IL-12 did not have any beneficial effect on IFN-
production by T
cells in the presence of CD40-triggered DC, which already secrete
IL-12, and only slightly increased IFN-
production induced by
uninfected immature DC at high T-cell/DC ratios. In conclusion, the
upregulation of costimulatory and MHC molecules on rAd-infected DC
correlates with increased T-cell stimulatory functions. The inability
of rAd to trigger IL-12 secretion by DC is responsible for the poor induction of IFN-
secretion by activated T cells.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
rAd-infected DC are more potent immunostimulatory APC
than their noninfected counterparts, and exogenous IL-12 further
increases their T-cell stimulatory functions. HLA-DR3-matched immature
DC were pulsed with 10 µg of p3-13 per ml for 2 h at 37°C,
washed extensively, and subsequently cultured in medium control ( ),
infected with AdCMV -gal at 1,000 PFU/cell ( ), or allowed to
mature with CD8-CD40L ( ). After 48 h, various numbers of DC
were incubated with Th1 clone Rp15 1-1 in the absence (open symbols) or
presence (solid symbols) of exogenous IL-12 ( [immature DC], [infected DC], and [mature DC]). T-cell proliferation (A) and
T-cell-derived IFN- production (B) were measured after 3 days. DC
pulsed with a control DR3-binding peptide failed to induce T-cell
proliferation and IFN- production (data not shown). The results are
representative of three independent experiments.
|
|
rAd infection and CD40 ligation act in synergy to trigger DC
maturation.
The intermediate activation state of rAd-infected DC
suggested either that the activation signals provided by rAd were
insufficient to trigger full DC maturation or that full DC maturation
was prevented by a second, counteracting rAd effect. To discriminate
between these possibilities, DC infected with AdCMV
-gal were
stimulated through CD40 with the CD8-CD40L fusion protein. DC viability
and recovery were comparable in infected and noninfected cultures (data
not shown). CD40 ligation on rAd-infected DC resulted in the strong
upregulation of the DC maturation marker CD83 (Fig. 6A) and in the secretion of IL-12 (Fig.
6B, left panel). The level of production of IL-12 by rAd-infected
CD40-triggered DC was even higher than that observed with noninfected
CD40-triggered DC (up to twofold). In contrast, the secretion of IL-10
by CD40-triggered DC was not enhanced by the presence of rAd (Fig. 6B,
right panel). Similar results were obtained when rAd-infected DC pulsed
with the p3-13-specific peptide epitope were activated by Th1 clone RP15 1-1, a process that involved CD40-CD40L interactions (8, 32). The synergistic effect of rAd infection and CD40 ligation on
DC maturation was also reflected by the capacity of DC pulsed with
hsp65 to stimulate both secondary p3-13-specific and rAd-specific CD4+ Th1-type responses in cultures from
HLA-DR3+ individuals (Fig.
7). Both proliferation and IFN-
production were optimally induced by rAd-infected DC triggered through
CD40.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
CD40 triggering of rAd-infected DC induces CD83
expression and high levels of IL-12 production. Immature DC were
infected with AdCMV -gal at 1,000 PFU/cell, further incubated with
CD8-CD40L (rAd CD8-CD40L histogram) or not so incubated (rAd
histogram), and compared with their uninfected counterpart (medium and
CD8-CD40L historgrams). (A) CD83 expression was analyzed 48 h
later by flow cytometry. White histograms show background staining with
isotype control antibodies, and black histograms show specific
staining. (B) IL-12 and IL-10 were detected in the culture supernatants
after 48 h by an ELISA. The results are representative of five
independent experiments.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7.
rAd acts in synergy with CD40 triggering for the
development of Th1 immunostimulatory DC. Immature DC from
HLA-DR3+ individuals were pulsed with 10 µg of the hsp65
protein per ml and further cultured in medium only (white bars),
infected with AdCMV -gal (stippled bars), allowed to mature with
CD8-CD40L (grey bars), or infected with AdCMV -gal and allowed to
mature with CD8-CD40L (black bars). DC were cocultured with autologous
responders 48 h later. After 5 days, T cells were expanded with
TCGF for 8 additional days. Responders were subsequently cocultured
with autologous feeders and tested for the presence of p3-13-specific
(A) and rAd-specific (B) T cells by measuring proliferation and IFN-
production. The 70K peptide is a DR3-binding negative control peptide.
For proliferation, results are the mean ± standard deviation cpm
in triplicate wells. Comparable results were obtained with cells from
two different HLA-DR3+ individuals.
|
|
In conclusion, rAd do not counteract CD40-induced DC maturation, and
rAd-derived signals even act in synergy with CD40 signals to promote
the full maturation of rAd-infected DC.
 |
DISCUSSION |
We demonstrate that rAd infection induces partial maturation of
human monocyte-derived DC, thereby increasing the immunostimulatory functions of these APC. However, efficient infection requires high MOI,
in agreement with previous reports by others (1, 14). This
finding can be readily explained by our observation that DC lack
surface expression of CAR, which serves as a high-affinity receptor for
the adenovirus fiber protein and through which this virus can
efficiently attach to cells (4). MHC class I molecules and
M
2 integrins may serve as alternative receptors for
fiber-mediated and penton-mediated rAd attachment, respectively
(23, 25). However, since DC express considerable levels of
these molecules, these alternative adhesion pathways do not appear to
efficiently compensate for the lack of CAR, as observed for hamster
cells (12). On the other hand, a major blockade for DC
infection may also lie downstream of the attachment stage, at the
internalization stage, for which
V
3 and
V
5 integrins are
important (51). Immature DC express
V
5 but lack
V
3. Interestingly,
V
5 expression decreases upon DC
maturation, a result which correlates with our observation that mature
DC are even less permissive to rAd. Taken together, our data indicate
that the low permissiveness of DC results from poor adhesion and
internalization of rAd.
At present, we cannot exclude the possibility that the poor
permissiveness of DC to rAd infection reflects additional hurdles in
the infection pathway. In fact, a comparison of different types of
mature DC shows that
V
5 integrin expression is downmodulated in
all cases, whereas the permissiveness of only poly(I · C)- and
LPS-activated DC is severely reduced. Poly(I · C)- and
LPS-stimulated DC produce high levels of IFN-
/
prior to viral
infection (10). IFN-
/
may provide an early and
efficient line of defense of these DC against rAd, before
virus-associated RNAs can inhibit the antiviral effects of IFN-
/
(28).
Irrespective of these considerations, our data clearly argue that
immature DC rather than mature DC constitute the target cell of choice
for rAd-mediated gene transfer. It will be important to search for
means to increase the efficiency of the attachment and internalization
steps. The development of rAd with modified fiber and penton proteins
which can target surface proteins that are abundantly available at the
DC surface or of dual-specificity antibodies which can link the rAd
capsid proteins to such DC surface molecules (49) represents
a logical step in this direction.
Our study reveals that rAd infection leads to the upregulation of
costimulatory and MHC molecules and increases the T-cell stimulatory
functions of DC. However, rAd-infected DC are not fully mature, as
shown by the very low levels of CD83 and the absence of IL-12
secretion. These results contrast with the recent report of Zhong et
al. (53), who interpreted rAd infection as a neutral event
for DC. A careful analysis of their data reveals that the cells used as
immature DC already expressed low levels of the maturation marker CD83.
The moderate effects of rAd on such DC may be difficult to discriminate
from spontaneous activation due to culture conditions. It is important
to note that the capacity of rAd to induce the expression of the
adhesion molecule CD54 has been reported for human airway epithelial
cells (32, 34, 47). Combined with our results, these studies
indicate that rAd upregulate the expression of molecules involved in
immune and inflammatory responses in both APC and non-APC populations.
We show that rAd-infected DC are less potent APC than CD40-triggered
DC, a result which correlates with the partial upregulation of
costimulatory and MHC molecules on rAd-infected DC and with the lack of
IL-12 production. We found that exogenous IL-12 enhanced the secretion
of IFN-
by T cells stimulated with rAd-infected DC but did not
affect T-cell proliferation. Our results differ from earlier reports
showing that IL-12 upregulates both proliferation and IFN-
secretion
by Th1 clones (27, 31); this discrepancy in results may be
explained by different experimental conditions. These reports indeed
made use of total spleen cells as APC instead of DC. Importantly, we
show that rAd-infected DC do not produce the immunoregulatory cytokine
IL-10. In addition, unlike other viruses, rAd do not counteract the
full maturation of DC through CD40 and even act in synergy with CD40
signals to promote the development of rAd-infected DC into typical
Th1-inducing DC.
Most of the recently developed rAd vectors not only lack the E1 region
but have a deletion of one or more of the other early regions
(30). Since efficient infection of DC requires high MOI,
whereas expression of the viral genome at high MOI is not strictly
dependent on a functional E1 protein, we tested whether the presence or
absence of the different early regions affected rAd-induced DC
activation. Our data show that all rAd with deletions induce DC
activation comparable to that of wild-type adenovirus, indicating that
the E1, E2A, E3, and E4 regions have neither a negative nor a positive
effect on this activation process. This finding implies that
rAd-induced DC activation involves other mechanisms which may relate to
late-gene expression. Testing this hypothesis will require the analysis
of mutants carrying deletions in the late regions of the adenovirus
genome. More importantly, our data indicate that rAd infection enhances
the immunostimulatory characteristics of DC regardless of the type of
rAd tested so far, a finding which implies that all of these rAd
vectors can be safely used for this application.
Our findings provide new insights into the interactions between rAd and
human DC and are important for the use of rAd-infected DC in
immune-intervention strategies. The fact that rAd infection enhances DC
function supports the suitability of rAd-infected DC as vaccines
against infectious agents or tumor antigens. The failure of rAd to
trigger the activation of DC into fully mature Th1-inducing APC
indicates that optimization requires additional triggering of DC
through their CD40 receptor. Importantly, rAd infection and CD40
triggering act in synergy, in that this combination results in fully
mature DC that show a higher level of IL-12 secretion and T-cell
stimulatory potential than DC triggered either by rAd or through CD40
alone. The application of rAd-infected DC as vaccines should therefore
preferentially involve CD40 triggering prior to administration in vivo.
On the other hand, further in vivo activation of rAd-infected DC may be
driven by the interaction with Th cells against rAd-derived antigens,
for which memory exists in most individuals.
 |
ACKNOWLEDGMENTS |
We thank Francine Briere and Pierre Garrone (Schering-Plough,
Dardilly, France) for kindly providing the CD8-CD40L fusion protein,
Krista van Meijgaarden and Tom Ottenhoff for providing the RP15 1-1 clone, Martijn Rabelink for expert assistance, A. H. Zwinderman
for statistical analysis, and Sjoerd van den Burg for critical reading
of the manuscript.
This work was supported by the European Union (TMR contract
FMRX-CT0053), by the Dutch Cancer Society (project 97-1450), by the
Dutch Praeventiefonds, and by The Netherlands Organization of
Scientific Research (NWO).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Immunohematology and Blood Bank, Building E3-Q, Leiden University
Medical Center, Postbus 9600, 2300 RC Leiden, The Netherlands. Phone: 31 71 526 4007. Fax: 31 71 521 6751. E-mail:
D.G.Rea{at}Immunohematology.Medfac.Leidenuniv.nl.
 |
REFERENCES |
| 1.
|
Arthur, J. F.,
L. H. Butterfield,
M. D. Roth,
L. A. Bui,
S. M. Kiertscher,
R. Lau,
S. Dubinett,
J. Glaspy,
W. H. McBride, and J. S. Economou.
1997.
A comparison of gene transfer methods in human dendritic cells.
Cancer Gene Ther.
4:17-25[Medline].
|
| 2.
|
Banchereau, J., and R. M. Steinman.
1998.
Dendritic cells and the control of immunity.
Nature
392:245-251[Medline].
|
| 3.
|
Bender, A.,
M. Sapp,
G. Schuler,
R. M. Steinman, and N. Bhardwaj.
1996.
Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood.
J. Immunol. Methods
196:121-135[Medline].
|
| 4.
|
Bergelson, J. M.,
J. A. Cunningham,
G. Droguett,
E. A. Kurt-Jones,
A. Krithivas,
J. S. Hong,
M. S. Horwitz,
R. L. Croell, and R. W. Finberg.
1997.
Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.
Science
275:1320-1323[Abstract/Free Full Text].
|
| 5.
|
Bhardwaj, N.
1997.
Interactions of viruses with dendritic cells: a double-edged sword.
J. Exp. Med.
186:795-799[Free Full Text].
|
| 6.
|
Brossart, P.,
A. W. Goldrath,
E. A. Butz,
S. Martin, and M. J. Bevan.
1997.
Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.
J. Immunol.
158:3270-3276[Abstract].
|
| 7.
|
Butterfield, L. H.,
S. M. Jilani,
N. G. Chakraborty,
L. A. Bui,
A. Ribas,
V. B. Dissette,
R. Lau,
S. C. Gamradt,
J. A. Glaspy,
W. H. McBride,
B. Mukherji, and J. S. Economou.
1998.
Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
J. Immunol.
161:5607-5613[Abstract/Free Full Text].
|
| 8.
|
Caux, C.,
C. Massacrier,
B. Vanbervliet,
B. Dubois,
C. van Kooten,
I. Durand, and J. Banchereau.
1994.
Activation of human dendritic cells through CD40 cross-linking.
J. Exp. Med.
180:1263-1272[Abstract/Free Full Text].
|
| 9.
|
Cella, M.,
D. Sheidegger,
K. Palmer-Lehman,
P. Lane,
A. Lanzavecchia, and G. Alber.
1996.
Ligation of CD40 on dendritic cells triggers the production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
J. Exp. Med.
184:747-792[Abstract/Free Full Text].
|
| 10.
|
Cella, M.,
M. Salio,
Y. Sakakibara,
H. Langen,
I. Julkunene, and A. Lanzavecchia.
1999.
Maturation, activation and protection of dendritic cells induced by double-stranded RNA.
J. Exp. Med.
189:1-9[Abstract/Free Full Text].
|
| 11.
|
Chen, P.,
J. Tian,
I. Kovesdi, and J. T. Bruner.
1998.
Interaction of the adenovirus 14.7kDa protein with FLICE inhibits Fas ligand-induced apoptosis.
J. Biol. Chem.
273:5815-5820[Abstract/Free Full Text].
|
| 12.
|
Davidson, E.,
I. Kirby, and G. Santis.
1999.
The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber.
J. Virol.
73:4513-4517[Abstract/Free Full Text].
|
| 13.
|
De Saint Vis, B.,
I. Fugier-Vivier,
C. Massacrier,
C. Gaillard,
B. Vanbervliet,
S. Ait-Yahia,
J. Banchereau,
Y.-J. Liu,
S. Lebecque, and C. Caux.
1998.
The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation.
J. Immunol.
160:1666-1676[Abstract/Free Full Text].
|
| 14.
|
Dietz, A. B., and S. Vuk-Pavlovic.
1998.
High efficiency adenovirus-mediated gene transfer to human dendritic cells.
Blood
91:392-398[Abstract/Free Full Text].
|
| 15.
|
Engering, A. J.,
M. Cella,
D. Fluitsma,
M. Brockhaus,
E. C. M. Hoefsmit,
A. Lanzavecchia, and J. Pieters.
1997.
The mannose receptor functions as high capacity and broad specificity antigen receptor in human dendritic cells.
Eur. J. Immunol.
27:2412-2425.
|
| 16.
|
Fallaux, F. J.,
O. Kranenburg,
S. J. Cramer,
A. Houweling,
H. van Ormondt,
R. C. Hoeben, and A. J. van der Eb.
1996.
Characterization of 911: a new helper cell line for the titration and propagation of early region 1 deleted adenoviral vectors.
Hum. Gene Ther.
7:215-222[Medline].
|
| 17.
|
Fugier-Vivier, I.,
C. Servet-Delprat,
P. Rivailler,
M. C. Rissoan,
Y. J. Liu, and C. R. Rabourdin Combe.
1997.
Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic cells.
J. Exp. Med.
186:813-823[Abstract/Free Full Text].
|
| 18.
|
Garrone, P.,
E.-M. Neidhardt,
E. Garcia,
L. Galibert,
C. van Kooten, and J. Banchereau.
1995.
Fas ligation induces apoptosis of CD40-activated human B lymphocytes.
J. Exp. Med.
182:1265-1273[Abstract/Free Full Text].
|
| 19.
|
Geluk, A.,
K. E. van Meijgaarden,
A. A. M. Janson,
J.-W. Drijfhout,
R. Meloen,
R. R. P. de Vries, and T. H. M. Ottenhoff.
1992.
Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17 binding motif and enables the design of allele-specific competitor peptides.
J. Immunol.
149:2864-2871[Abstract].
|
| 20.
|
Grosjean, I.,
C. Caux,
C. Bella,
I. Berger,
F. Wild,
J. Banchereau, and D. Kaiserlian.
1997.
Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells.
J. Exp. Med.
186:801-812[Abstract/Free Full Text].
|
| 21.
|
Herz, J., and R. D. Gerard.
1993.
Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice.
Proc. Natl. Acad. Sci. USA
90:2812-2816[Abstract/Free Full Text].
|
| 22.
|
Hidaka, C.,
E. Milano,
P. L. Leopold,
J. M. Bergelson,
N. R. Hackett,
R. W. Finberg,
T. J. Wickham,
I. Kovesdi,
P. Roelvink, and R. G. Crystal.
1999.
CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts.
J. Clin. Investig.
103:579-587[Medline].
|
| 23.
|
Hong, S. S.,
L. Karayan,
J. Tournier,
D. T. Curiel, and P. A. Boulanger.
1997.
Adenovirus type 5 fiber knob binds to MHC class I 2 domain at the surface of human epithelial and B lymphoblastoid cells.
EMBO J.
16:2294-2306[Medline].
|
| 24.
|
Hsu, K.-M. L.,
K. Lonberg-Holm,
B. Alstein, and R. L. Crowell.
1988.
A monoclonal antibody specific for the cellular receptor for group B coxsackieviruses.
J. Virol.
62:1647-1652[Abstract/Free Full Text].
|
| 25.
|
Huang, S.,
T. Kamata,
Y. Takada,
Z. M. Ruggeri, and G. R. Nemerow.
1996.
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells.
J. Virol.
70:4502-4508[Abstract].
|
| 26.
|
Kaplan, J. M.,
D. Armentano,
A. Scaria,
L. A. Woodworth,
S. E. Pennington,
S. C. Wadsworth,
A. E. Smith, and R. J. Gregory.
1999.
Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes.
J. Virol.
73:4489-4492[Abstract/Free Full Text].
|
| 27.
|
Kennedy, M. K.,
K. S. Picha,
K. D. Shanebeck,
D. M. Anderson, and K. H. Grabstein.
1994.
Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0 clones.
Eur. J. Immunol.
24:2271-2278[Medline].
|
| 28.
|
Kitajewski, J.,
R. J. Schneider,
B. Safer,
S. M. Munemitsu,
C. E. Samuel,
B. Thimmappaya, and T. Shenk.
1986.
Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced elF-2 kinase.
Cell
45:195-200[Medline].
|
| 29.
|
Koch, F.,
U. Stanzl,
P. Jennevin,
K. Janke,
C. Heufler,
E. Kampgen,
R. Romani, and G. Schuler.
1996.
High levels of IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.
J. Exp. Med.
184:741-746[Abstract/Free Full Text].
|
| 30.
|
Lusky, M.,
M. Christ,
K. Rittner,
A. Dieterle,
D. Dreyer,
B. Mourot,
H. Schultz,
F. Stoeckel,
A. Pavirani, and M. Mehtali.
1998.
In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
J. Virol.
72:2022-2032[Abstract/Free Full Text].
|
| 31.
|
Murphy, E. E.,
G. Terres,
S. E. Macatonia,
C.-S. Hsieh,
J. Mattson,
L. Lanier,
M. Wysocka,
G. Trinchieri,
K. Murphy, and A. O'Garra.
1994.
B7 and interleukin 12 cooperate for proliferation and interferon- production in mouse T helper clones that are unresponsive to B7 costimulation.
J. Exp. Med.
180:223-231[Abstract/Free Full Text].
|
| 32.
|
Nicolis, E.,
A. Tamanini,
P. Melotti,
R. Rolfini,
G. Berton,
M. A. Cassatella,
A. Bout,
A. Pavirani, and G. Cabrini.
1998.
ICAM-1 induction in respiratory cells exposed to a replication-deficient recombinant adenovirus in vitro and in vivo.
Gene Ther.
5:131-136[Medline].
|
| 33.
|
O'Garra, A.
1998.
Cytokines induce the development of functionally heterogeneous T helper cell subsets.
Immunity
8:275-283[Medline].
|
| 34.
|
Pilewski, J. M.,
D. J. Sott,
J. M. Wilson, and S. M. Abelda.
1995.
ICAM-1 expression on bronchial epithelium after recombinant adenovirus infection.
Am. J. Respir. Cell Mol. Biol.
12:142-148[Abstract].
|
| 35.
|
Ribas, A.,
L. H. Butterfield,
W. H. McBride,
S. M. Jilani,
L. A. Bui,
C. M. Vollmer,
R. Lau,
V. B. Dissett,
B. Hu,
A. Y. Chen,
J. A. Glaspy, and J. S. Economou.
1997.
Genetic immunization for the melanoma antigen MART-1/melan-A using recombinant adenovirus-transduced murine dendritic cells.
Cancer Res.
57:2865-2869[Abstract/Free Full Text].
|
| 36.
|
Ridge, J. P.,
F. Di Rosa, and P. Matzinger.
1998.
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.
Nature
393:474-478[Medline].
|
| 37.
|
Rissoan, M. C.,
V. Soumelis,
N. Kadowaki,
G. Grouard,
F. Briere,
R. de Waal Malefyt, and Y. J. Liu.
1999.
Reciprocal control of helper cell and dendritic cell differentiation.
Science
283:1183-1186[Abstract/Free Full Text].
|
| 38.
|
Romani, N.,
S. Gruner,
D. Brang,
E. Kampgen,
A. Lenz,
B. Trockenbacher,
G. Konwalinka,
P. O. Fritsch,
R. M. Steinman, and G. Schuler.
1994.
Proliferating dendritic cell progenitors in human blood.
J. Exp. Med.
180:83-93[Abstract/Free Full Text].
|
| 39.
|
Romani, N.,
D. Reider,
M. Heuer,
S. Ebner,
E. Kampgen,
B. Eibl,
D. Niederwieser, and G. Schuler.
1996.
Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability.
J. Immunol. Methods
196:137-151[Medline].
|
| 40.
|
Sallusto, F.,
M. Cella,
C. Danieli, and A. Lanzavecchia.
1995.
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
J. Exp. Med.
182:389-400[Abstract/Free Full Text].
|
| 41.
|
Sallusto, F., and A. Lanzavecchia.
1994.
Efficient presentation of soluble antigens by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor and downregulated by tumor necrosis factor .
J. Exp. Med.
179:1109-1118[Abstract/Free Full Text].
|
| 42.
|
Schagen, F. H. E.,
A. C. E. Moor,
C. Cheong,
S. J. Cramer,
H. van Ormondt,
A. J. van der Eb,
T. M. A. R. Dubbelman, and R. C. Hoeben.
1999.
Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation.
Gene Ther.
6:873-881[Medline].
|
| 43.
|
Schnorr, J. J.,
S. Xanthakos,
P. Keikavoussi,
E. Kampgen,
V. T. Meulen, and S. Schneider-Schaulies.
1997.
Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression.
Proc. Natl. Acad. Sci. USA
94:5326-5331[Abstract/Free Full Text].
|
| 44.
|
Servat-Delprat, C.,
P. O. Viladain,
K. Ravanel, and C. Rabourdin-Combe.
1998.
Abnormal differentiation of measles virus-infected human dendritic cells, abstr. E33, p. 64.
In
5th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology 1998
|
| 45.
|
Shisler, J.,
C. Yang,
B. Walter,
C. F. Ware, and L. R. Gooding.
1997.
The adenovirus E3-10.4/14.5 complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis.
J. Virol.
71:8299-8306[Abstract].
|
| 46.
|
Song, W.,
H. Kong,
H. Carpenter,
H. Torii,
R. Granstein,
S. Rafii,
M. A. S. Moore, and R. G. Crystal.
1997.
Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity.
J. Exp. Med.
186:1247-1256[Abstract/Free Full Text].
|
| 47.
|
Stark, J. M.,
R. S. Amin, and B. C. Trapnell.
1996.
Infection of A549 cells with a recombinant adenovirus vector induces ICAM-1 expression and increased CD18-dependent adhesion of activated neutrophils.
Hum. Gene Ther.
7:1669-1681[Medline].
|
| 48.
|
Tan, M. C. A. A.,
A. A. Mommaas,
J.-W. Drijfhout,
R. Jordens,
J. J. M. Onderwater,
D. Verwoerd,
A. A. Mulder,
A. N. van der Heiden,
D. Scheidegger,
L. C. J. M. Oomens,
T. H. M. Ottenhoff,
A. Tulp,
J. J. Neefjes, and F. Koning.
1997.
Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells.
Eur. J. Immunol.
27:2426-2435[Medline].
|
| 49.
|
Tillman, B. W.,
T. D. de Gruijl,
S. A. Luyks-de Bakker,
R. J. Scheper,
H. M. Pinedo,
T. J. Curiel,
W. R. Gerriten, and D. T. Curiel.
1999.
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector.
J. Immunol.
162:6378-6383[Abstract/Free Full Text].
|
| 50.
|
Wan, Y.,
J. Bramson,
R. Carter,
F. Graham, and J. Gaudie.
1997.
Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination.
Hum. Gene Ther.
8:1355-1363[Medline].
|
| 51.
|
Wickham, T. J.,
P. Mathias,
D. A. Cheresh, and G. R. Nemerow.
1993.
Integrins V 3 and V 5 promote adenovirus internalization but not virus attachment.
Cell
73:309-319[Medline].
|
| 52.
|
Wold, W. S. M., and L. R. Gooding.
1991.
Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions.
Virology
184:1-8[Medline].
|
| 53.
|
Zhong, L.,
A. Granelli-Piperno,
Y. Cho, and R. M. Steinman.
1999.
Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells.
Eur. J. Immunol.
29:964-972[Medline].
|
Journal of Virology, December 1999, p. 10245-10253, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lore, K., Adams, W. C., Havenga, M., Precopio, M. L., Holterman, L., Goudsmit, J., Koup, R. A.
(2007). Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses. J. Immunol.
179: 1721-1729
[Abstract]
[Full Text]
-
Perreau, M., Mennechet, F., Serratrice, N., Glasgow, J. N., Curiel, D. T., Wodrich, H., Kremer, E. J.
(2007). Contrasting Effects of Human, Canine, and Hybrid Adenovirus Vectors on the Phenotypical and Functional Maturation of Human Dendritic Cells: Implications for Clinical Efficacy. J. Virol.
81: 3272-3284
[Abstract]
[Full Text]
-
Tang, Q., Maul, G. G.
(2006). Mouse cytomegalovirus crosses the species barrier with help from a few human cytomegalovirus proteins.. J. Virol.
80: 7510-7521
[Abstract]
[Full Text]
-
Thiele, A. T., Sumpter, T. L., Walker, J. A., Xu, Q., Chang, C.-H., Bacallao, R. L., Kher, R., Wilkes, D. S.
(2006). Pulmonary Immunity to Viral Infection: Adenovirus Infection of Lung Dendritic Cells Renders T Cells Nonresponsive to Interleukin-2. J. Virol.
80: 1826-1836
[Abstract]
[Full Text]
-
Schoggins, J. W., Nociari, M., Philpott, N., Falck-Pedersen, E.
(2005). Influence of Fiber Detargeting on Adenovirus-Mediated Innate and Adaptive Immune Activation. J. Virol.
79: 11627-11637
[Abstract]
[Full Text]
-
Bellemare-Pelletier, A., Tremblay, J., Beaulieu, S., Boulassel, M.-R., Routy, J.-P., Massie, B., Lapointe, R., Thibodeau, J.
(2005). HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing. J. Leukoc. Biol.
78: 95-105
[Abstract]
[Full Text]
-
Tan, P. H., Beutelspacher, S. C., Xue, S.-A., Wang, Y.-H., Mitchell, P., McAlister, J. C., Larkin, D. F. P., McClure, M. O., Stauss, H. J., Ritter, M. A., Lombardi, G., George, A. J. T.
(2005). Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood
105: 3824-3832
[Abstract]
[Full Text]
-
Murakami, T., Tokunaga, N., Waku, T., Gomi, S., Kagawa, S., Tanaka, N., Fujiwara, T.
(2004). Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene. Clin. Cancer Res.
10: 3871-3880
[Abstract]
[Full Text]
-
Philpott, N. J., Nociari, M., Elkon, K. B., Falck-Pedersen, E.
(2004). Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-{alpha} induction pathway. Proc. Natl. Acad. Sci. USA
101: 6200-6205
[Abstract]
[Full Text]
-
Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P. L., Aldrich, W. A., Banerjee, P. T., Gillies, S. D., Curiel, D. T., Krasnykh, V.
(2003). Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells. J. Virol.
77: 11367-11377
[Abstract]
[Full Text]
-
Molinier-Frenkel, V., Prevost-Blondel, A., Hong, S.-S., Lengagne, R., Boudaly, S., Magnusson, M. K., Boulanger, P., Guillet, J.-G.
(2003). The Maturation of Murine Dendritic Cells Induced by Human Adenovirus Is Mediated by the Fiber Knob Domain. J. Biol. Chem.
278: 37175-37182
[Abstract]
[Full Text]
-
Tritel, M., Stoddard, A. M., Flynn, B. J., Darrah, P. A., Wu, C.-y., Wille, U., Shah, J. A., Huang, Y., Xu, L., Betts, M. R., Nabel, G. J., Seder, R. A.
(2003). Prime-Boost Vaccination with HIV-1 Gag Protein and Cytosine Phosphate Guanosine Oligodeoxynucleotide, Followed by Adenovirus, Induces Sustained and Robust Humoral and Cellular Immune Responses. J. Immunol.
171: 2538-2547
[Abstract]
[Full Text]
-
Wang, X., Messerle, M., Sapinoro, R., Santos, K., Hocknell, P. K., Jin, X., Dewhurst, S.
(2003). Murine Cytomegalovirus Abortively Infects Human Dendritic Cells, Leading to Expression and Presentation of Virally Vectored Genes. J. Virol.
77: 7182-7192
[Abstract]
[Full Text]
-
Jongmans, W., Tiemessen, D. M., Oosterwijk, E., Mulders, P. F. A.
(2003). Correspondence re: Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, D. Carey, and D. T. Curiel, Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors. Cancer Res., 62: 4273-4281, 2002.. Cancer Res.
63: 1994-1995
[Full Text]
-
Woltman, A. M., van der Kooij, S. W., Coffer, P. J., Offringa, R., Daha, M. R., van Kooten, C.
(2003). Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood
101: 1439-1445
[Abstract]
[Full Text]
-
de Gruijl, T. D., Luykx-de Bakker, S. A., Tillman, B. W., van den Eertwegh, A. J. M., Buter, J., Lougheed, S. M., van der Bij, G. J., Safer, A. M., Haisma, H. J., Curiel, D. T., Scheper, R. J., Pinedo, H. M., Gerritsen, W. R.
(2002). Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. J. Immunol.
169: 5322-5331
[Abstract]
[Full Text]
-
Miller, G., Lahrs, S., Pillarisetty, V. G., Shah, A. B., DeMatteo, R. P.
(2002). Adenovirus Infection Enhances Dendritic Cell Immunostimulatory Properties and Induces Natural Killer and T-Cell-mediated Tumor Protection. Cancer Res.
62: 5260-5266
[Abstract]
[Full Text]
-
Nakamura, M., Iwahashi, M., Nakamori, M., Ueda, K., Matsuura, I., Noguchi, K., Yamaue, H.
(2002). Dendritic Cells Genetically Engineered to Simultaneously Express Endogenous Tumor Antigen and Granulocyte Macrophage Colony-stimulating Factor Elicit Potent Therapeutic Antitumor Immunity. Clin. Cancer Res.
8: 2742-2749
[Abstract]
[Full Text]
-
Oberholzer, A., Oberholzer, C., Bahjat, K. S., Ungaro, R., Tannahill, C. L., Murday, M., Bahjat, F. R., Abouhamze, Z., Tsai, V., LaFace, D., Hutchins, B., Moldawer, L. L., Clare-Salzler, M. J.
(2002). Increased Survival in Sepsis by In Vivo Adenovirus-Induced Expression of IL-10 in Dendritic Cells. J. Immunol.
168: 3412-3418
[Abstract]
[Full Text]
-
Havenga, M. J. E., Lemckert, A. A. C., Ophorst, O. J. A. E., van Meijer, M., Germeraad, W. T. V., Grimbergen, J., van den Doel, M. A., Vogels, R., van Deutekom, J., Janson, A. A. M., de Bruijn, J. D., Uytdehaag, F., Quax, P. H. A., Logtenberg, T., Mehtali, M., Bout, A.
(2002). Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease. J. Virol.
76: 4612-4620
[Abstract]
[Full Text]
-
Mercier, S., Gahery-Segard, H., Monteil, M., Lengagne, R., Guillet, J.-G., Eloit, M., Denesvre, C.
(2002). Distinct Roles of Adenovirus Vector-Transduced Dendritic Cells, Myoblasts, and Endothelial Cells in Mediating an Immune Response against a Transgene Product. J. Virol.
76: 2899-2911
[Abstract]
[Full Text]
-
Lyakh, L. A., Koski, G. K., Young, H. A., Spence, S. E., Cohen, P. A., Rice, N. R.
(2002). Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14+ monocytes cultured under serum-free conditions. Blood
99: 600-608
[Abstract]
[Full Text]
-
Molinier-Frenkel, V., Lengagne, R., Gaden, F., Hong, S.-S., Choppin, J., Gahery-Segard, H., Boulanger, P., Guillet, J.-G.
(2002). Adenovirus Hexon Protein Is a Potent Adjuvant for Activation of a Cellular Immune Response. J. Virol.
76: 127-135
[Abstract]
[Full Text]
-
Okada, N., Saito, T., Masunaga, Y., Tsukada, Y., Nakagawa, S., Mizuguchi, H., Mori, K., Okada, Y., Fujita, T., Hayakawa, T., Mayumi, T., Yamamoto, A.
(2001). Efficient Antigen Gene Transduction Using Arg-Gly-Asp Fiber-Mutant Adenovirus Vectors Can Potentiate Antitumor Vaccine Efficacy and Maturation of Murine Dendritic Cells. Cancer Res.
61: 7913-7919
[Abstract]
[Full Text]
-
Mikloska, Z., Bosnjak, L., Cunningham, A. L.
(2001). Immature Monocyte-Derived Dendritic Cells Are Productively Infected with Herpes Simplex Virus Type 1. J. Virol.
75: 5958-5964
[Abstract]
[Full Text]
-
Libraty, D. H., Pichyangkul, S., Ajariyakhajorn, C., Endy, T. P., Ennis, F. A.
(2001). Human Dendritic Cells Are Activated by Dengue Virus Infection: Enhancement by Gamma Interferon and Implications for Disease Pathogenesis. J. Virol.